product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
Wee1 (D10D2) Rabbit mAb
catalog :
13084
clonality :
monoclonal
host :
domestic rabbit
conjugate :
nonconjugated
clone name :
D10D2
reactivity :
human, mouse
application :
western blot, immunohistochemistry, immunohistochemistry - paraffin section
more info or order :
Cell Signaling Technology product webpage
citations: 6
Published Application/Species/Sample/DilutionReference
  • immunohistochemistry - paraffin section; human; 1:200; loading ...; fig 1e
  • western blot; human; 1:1000; loading ...; fig 2c, 2d, 2e
Li C, Shen Q, Zhang P, Wang T, Liu W, Li R, et al. Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy via activating cGAS/STING signaling in gastric cancer cells. J Exp Clin Cancer Res. 2021;40:315 pubmed publisher
  • immunohistochemistry; human; 1:200; loading ...; fig 4i
  • western blot; mouse; 1:1000; loading ...; fig 3c
Jokoji G, Maeda S, Oishi K, Ijuin T, Nakajima M, Tawaratsumida H, et al. CDC5L promotes early chondrocyte differentiation and proliferation by modulating pre-mRNA splicing of SOX9, COL2A1, and WEE1. J Biol Chem. 2021;297:100994 pubmed publisher
  • western blot; human; 1:1000; loading ...; fig s5c
Grandits A, Nguyen C, Schlerka A, Hackl H, Sill H, Etzler J, et al. Downregulation of MTSS1 in acute myeloid leukemia is associated with a poor prognosis, chemotherapy resistance, and disease aggressiveness. Leukemia. 2021;35:2827-2839 pubmed publisher
  • western blot; human; loading ...; fig 3d
Osei Amponsa V, Sridharan V, Tandon M, Evans C, Klarmann K, Cheng K, et al. Impact of losing hRpn13 Pru or UCHL5 on proteasome clearance of ubiquitinated proteins and RA190 cytotoxicity. Mol Cell Biol. 2020;: pubmed publisher
  • western blot; human; loading ...; fig 5e, s3b
Liu G, Zhang Q, Xia L, Shi M, Cai J, Zhang H, et al. RNA-binding protein CELF6 is cell cycle regulated and controls cancer cell proliferation by stabilizing p21. Cell Death Dis. 2019;10:688 pubmed publisher
  • western blot; human; 1:1000; fig 4
Toledo C, Ding Y, Hoellerbauer P, Davis R, Basom R, Girard E, et al. Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells. Cell Rep. 2015;13:2425-2439 pubmed publisher
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
https://www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.